Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBIT Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed EBIT Margin for 16 consecutive years, with 1517.8% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 109062.0% to 1517.8% in Q3 2025 year-over-year; TTM through Sep 2025 was 193.76%, a 59440.0% increase, with the full-year FY2025 number at 117.62%, up 61085.0% from a year prior.
  • EBIT Margin was 1517.8% for Q3 2025 at IGC Pharma, down from 580.79% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 5040.74% in Q1 2021 to a low of 7764.29% in Q3 2021.
  • A 5-year average of 1286.92% and a median of 880.88% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: soared 1346488bps in 2021, then crashed -1036943bps in 2022.
  • IGC Pharma's EBIT Margin stood at 1679.58% in 2021, then skyrocketed by 60bps to 675.3% in 2022, then tumbled by -118bps to 1469.61% in 2023, then skyrocketed by 50bps to 730.74% in 2024, then crashed by -108bps to 1517.8% in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBIT Margin are 1517.8% (Q3 2025), 580.79% (Q2 2025), and 1375.45% (Q1 2025).